Pharmacodynamics and pharmacokinetics. (A) PIA results (expressed as the percentage of P-FLT3 relative to baseline) from trough (before dose) time points on days 8 and 15 of cycle 1 are plotted according to dose level. The solid black line indicates the mean. (B) PIA results plotted against plasma concentration of FF-10101. Whole blood collected at designated time points throughout cycle 1 of each dose level was analyzed for both FF-10101 concentration by mass spectrometry as well as to quantify the percentage of P-FLT3 relative to baseline using the PIA assay. (C) Plasma concentration of FF-10101 after dosing on cycle 2 day 1 for daily dosing cohorts. (D) Plasma concentration of FF-10101 after dosing on cycle 2 day 1 for BID dosing cohorts.